Mankind Pharma extends winning streak to four days, hitting a new record high

Mankind Pharma continues to grab headlines as its shares extended their rally for the fourth consecutive day, hitting a fresh record high of Rs 2,709.95 on September 24. The stock has soared nearly 12% over the past four sessions, signalling strong investor confidence. As of 11.48 am today, shares were trading at Rs 2,663.90 on the NSE, reflecting its solid market value.

This surge has sparked renewed interest among those looking to invest in stocks, particularly with Mankind Pharma's upbeat growth prospects. The company's recent plans to acquire Bharat Serums and Vaccines (BSV) have further fuelled optimism. According to brokerage firm Investec, Mankind's strong execution capabilities, combined with BSV's expertise in super-specialties, create a strategic advantage that could lead to sustained long-term growth.

Bullish technical indicators for further upside

From a technical standpoint, Mankind Pharma's charts also reflect a bullish formation. Senior Technical Analyst Pravesh Gour from Swastika Investmart pointed out that the stock has formed a bullish flag pattern, suggesting further upside potential. "The immediate resistance is at Rs 2,700, with Rs 2,800 being the next target. On the downside, Rs 2,600 acts as strong support," Gour noted. For those who invest in stocks, this upward trend could present a lucrative opportunity.

Strong market position and strategic vision

Mankind Pharma's strategic acquisition of BSV is expected to enhance its research, development, and sourcing capabilities, giving it a competitive edge in specialised sectors. Investec also believes that BBSV's speciality business is currently undervalued, with significant long-term growth potential that will benefit Mankind's overall vision. Investors seeking to invest in stocks may find this an exciting development as the company's growth trajectory appears robust.

Key takeaways

• Mankind Pharma hits a fresh record high, extending gains to nearly 12% in four days.
• Technical indicators suggest further upside, with a target of Rs 2,800.
• Acquisition of Bharat Serums and Vaccines could provide long-term strategic advantages.